News, Links and Commentary
Tuesday, November 09, 2004
Canadian Gene Therapy May Inhibit Photoreceptor Death
Robert Korneluk Ph.D, director of the Solange Gauthier Karsh Laboratory in Ottawa, recently announced that a gene therapy currently being investigated may be available in three years time:
The announcement was made during a presentation at The Foundation Fighting Blindness - Canada's Vision Quest 2004 conference, held on 6 November in Ottawa.
The disease [RP] is caused when genetic defects lead the cells in the retina to die prematurely. Mr. Korneluk and his coworkers, who are conducting research on XIAP, the X-linked inhibitor of apoptosis (cell death), believe that XIAP therapy can make the retina's photoreceptor cells more resistant to dying, and therefore preserve sight.
'Researcher touts 'potent' gene therapy', The Ottawa Citizen, 7 November 2004.
The announcement was made during a presentation at The Foundation Fighting Blindness - Canada's Vision Quest 2004 conference, held on 6 November in Ottawa.
Comments:
Post a Comment
